{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-030764","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.454135+00:00","generated_at":"2026-05-31T11:06:24.246342+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Lantern Pharma Q2 net loss $4.96M; LP-300 Harmonic trial 86% CBR","bullets":["Net loss of $4.96M ($0.46/shr) for Q2 2024 vs $4.75M ($0.44/shr) a year ago; cash $33.3M at June 30.","LP-300 Harmonic Phase 2 lead-in (7 pts): 86% clinical benefit rate, 43% objective response rate, no dose-limiting toxicities.","LP-184 Phase 1A: 7 cohorts dosed, no DLTs; LP-284 third cohort dosing, no DLTs; both on track.","RADR platform collaboration with Oregon Therapeutics for XCE853; Starlight Therapeutics advancing STAR-001 for recurrent GBM.","Japanese patent issued for LP-284; Webinar Wednesdays launched for AI and oncology."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-030764","json":"https://secwatch.observer/filing/0001493152-24-030764.json","markdown":"https://secwatch.observer/filing/0001493152-24-030764.md","text":"https://secwatch.observer/filing/0001493152-24-030764.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224030764/0001493152-24-030764-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315224030764/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:06:24.246342+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}